Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription


1 AJR Am J Roentgenol
1 BJU Int
1 BMC Cancer
1 Br J Cancer
2 Cancer Imaging
1 Cancer Res
2 Int J Urol
1 J Magn Reson Imaging
1 J Nucl Med
2 J Urol
1 Magn Reson Imaging
1 Nat Rev Urol
1 PLoS One
3 Prostate
2 Radiol Imaging Cancer

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. WARD RD, Purysko AS
    Beyond the AJR: Biparametric MRI-Based Prostate Cancer Screening-A Cost-Effective Alternative to PSA Screening and Standard Biopsy.
    AJR Am J Roentgenol. 2023 Jan 18. doi: 10.2214/AJR.23.29011.

    BJU Int

  2. CUSSENOT O, Renard-Penna R, Montagne S, Ondet V, et al
    Clinical performance of MRI & biomarkers for prostate cancer diagnosis in men at high genetic risk.
    BJU Int. 2023 Jan 17. doi: 10.1111/bju.15968.
    PubMed         Abstract available

    BMC Cancer

  3. LIU Z, Zhu X, He J, Lu J, et al
    Metabolic syndrome and its components predict the biochemical recurrence and adverse pathological features of patients following radical prostatectomy: a propensity score matching study.
    BMC Cancer. 2023;23:50.
    PubMed         Abstract available

    Br J Cancer

  4. BAO J, Hou Y, Qin L, Zhi R, et al
    High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade.
    Br J Cancer. 2023 Jan 17. doi: 10.1038/s41416-022-02134.
    PubMed         Abstract available

    Cancer Imaging

  5. LIU X, Zhu Z, Wang K, Zhang Y, et al
    Semiautomated pelvic lymph node treatment response evaluation for patients with advanced prostate cancer: based on MET-RADS-P guidelines.
    Cancer Imaging. 2023;23:7.
    PubMed         Abstract available

  6. HU L, Fu C, Song X, Grimm R, et al
    Automated deep-learning system in the assessment of MRI-visible prostate cancer: comparison of advanced zoomed diffusion-weighted imaging and conventional technique.
    Cancer Imaging. 2023;23:6.
    PubMed         Abstract available

    Cancer Res

  7. PATTERSON JC, Varkaris A, Croucher PJP, Ridinger M, et al
    Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.
    Cancer Res. 2023;83:219-238.
    PubMed         Abstract available

    Int J Urol

    Editorial Comment on a national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer.
    Int J Urol. 2023 Jan 18. doi: 10.1111/iju.15142.

  9. YAMAGUCHI H, Kato T, Ishikawa Y, Takemasa K, et al
    Safety of hydrogel spacers for rectal wall protection in patients with prostate cancer: A retrospective analysis of 200 consecutive cases.
    Int J Urol. 2023 Jan 18. doi: 10.1111/iju.15140.
    PubMed         Abstract available

    J Magn Reson Imaging

    Editorial for "Deep-Learning Models for Detection and Localization of Visible Clinically Significant Prostate Cancer on Multi-Parametric MRI".
    J Magn Reson Imaging. 2023 Jan 20. doi: 10.1002/jmri.28609.

    J Nucl Med

  11. AL JALALI V, Wasinger G, Rasul S, Grubmueller B, et al
    Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naive prostate cancer.
    J Nucl Med. 2023 Jan 19:jnumed.122.264981. doi: 10.2967/jnumed.122.264981.
    PubMed         Abstract available

    J Urol

  12. TOUIJER K, Plata Bello A
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Reply.
    J Urol. 2023 Jan 19:101097JU0000000000003178. doi: 10.1097/JU.0000000000003178.

  13. DE BARROS HA, Berrens AC, Donswijk ML, Wit EMK, et al
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Letter.
    J Urol. 2023 Jan 17:101097JU0000000000003177. doi: 10.1097/JU.0000000000003177.

    Magn Reson Imaging

  14. GIBBONS M, Simko JP, Carroll PR, Noworolski SM, et al
    Prostate cancer lesion detection, volume quantification and high-grade cancer differentiation using cancer risk maps derived from multiparametric MRI with histopathology as the reference standard.
    Magn Reson Imaging. 2023 Jan 11:S0730-725X(23)00007.
    PubMed         Abstract available

    Nat Rev Urol

  15. LAWRENCE MG, Taylor RA, Cuffe GB, Ang LS, et al
    The future of patient-derived xenografts in prostate cancer research.
    Nat Rev Urol. 2023 Jan 17. doi: 10.1038/s41585-022-00706.
    PubMed         Abstract available

    PLoS One

  16. RAKAUSKAS A, Peters M, Martel P, van Rossum PSN, et al
    Do cancer detection rates differ between transperineal and transrectal micro-ultrasound mpMRI-fusion-targeted prostate biopsies? A propensity score-matched study.
    PLoS One. 2023;18:e0280262.
    PubMed         Abstract available


  17. DAVIDSSON S, Messing Eriksson A, Udumyan R, Swanholm P, et al
    Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
    Prostate. 2023 Jan 19. doi: 10.1002/pros.24485.
    PubMed         Abstract available

  18. RAM P, Nayak P, Mandal S, Das MK, et al
    Holmium laser enucleation of the prostate in men on active surveillance for prostate cancer with refractory lower urinary tract symptoms secondary to enlarged prostates.
    Prostate. 2023 Jan 19. doi: 10.1002/pros.24487.

  19. YANAGISAWA T, Hata K, Narita S, Hatakeyama S, et al
    Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
    Prostate. 2023 Jan 20. doi: 10.1002/pros.24488.
    PubMed         Abstract available

    Radiol Imaging Cancer

  20. DEEN SS
    Metabolic Phenotyping of Prostate Cancer Using Hyperpolarized (13)C MRI.
    Radiol Imaging Cancer. 2023;5:e239001.

  21. TAN KV
    Imaging Neuroendocrine Prostate Cancer with (89)Zr-labeled Delta-Like Ligand 3.
    Radiol Imaging Cancer. 2023;5:e239002.

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.